Cargando…
Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, plays an important role in the control of cell growth and differentiation. Disruption of its signaling leads to neoplastic cell proliferation, migration, stromal invasion, resistance to apoptosis,...
Autores principales: | Fakih, M., Vincent, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901793/ https://www.ncbi.nlm.nih.gov/pubmed/20680104 |
Ejemplares similares
-
Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010) -
KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010) -
Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2023) -
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
por: Doleschal, Bernhard, et al.
Publicado: (2022) -
Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy
por: Yang, Wentao, et al.
Publicado: (2022)